Corporate Events

Sony Semiconductor Solutions Corporation (Sony), SCREEN Holdings Co., Ltd. (SCREEN), and VitroVo Inc. (VitroVo) announced that they have jointly developed and will offer on a trial basis a microelectrode array (MEA) system powered by high-density CMOS-MEA*1 equipped with approximately 237,000 Electrodes. Combining Sony's advanced sensing devices, SCREEN Group's cellular electrical activity measurement technology, and VitroVo's MEA-driven compound evaluation and data analysis knowledge, the MEA system makes it possible to measure and record high-density cell activity data, which was previously difficult, and to visualize cellular activity in high definition. This innovation is aimed to contribute primarily to neuronal and cardiac disease research and drug discovery. In the field of drug research and development, improved accuracy in efficacy assessment and safety evaluation in nonclinical testing, and further streamlined development processes are in demand. There have been currently growing needs for the new methods with advanced technologies and microphysiological systems such as organoids, human iPSC- derived nerve cells and cardiomyocytes, which enable the high accurate evaluation of the effects of compounds on a human body without the usage of experimental animal. They can offer a new approach to animal testing which is currently mandatory prior to clinical trials of new drugs. Also, the acquisition of more sophisticated cell data is expected to contribute to disease research initiatives. The three companies have come together to develop the high-density MEA system with the cooperation of the Tohoku Institute of Technology (Tohtech). Based on cell electrical activity data, the system enables observation of the differences between diseased and healthy cells and the response of cells to compounds on the single cell level. More specifically, Sony's high-density CMOS- MEA, which is currently in development, and the SCREEN Group's cell electrical activity measurement technology were combined to detect extracellular electrical potential with the high-density array of microelectrodes, which is then output as image data. Through this process, users can monitor the cell firing, measure and record the reaction. Furthermore, the system is equipped with an algorithm optimized by VitroVo (based on joint research by Sony and Tohtech) for compound evaluation and an analysis software to enable better operability for users. This makes it possible to quickly display analysis results such as cell firing frequency as calculated from electrical potential and image measurement data, on a monitor. These measurement and analysis capabilities enable acquisition of cell activity data with greater density than with conventional methods, allowing users to obtain test results that were difficult with conventional measurement methods. This system can support research on disease phenotypes based on high-density cellular activity data and the risk assessment or the more efficient efficacy evaluation of compounds for new drugs as alternatives to animal testing. Because the system enables observation of neurons, it will also likely be used in the research and development of new drugs for mental illnesses such as depression and schizophrenia, neurological disorders such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease, as well as in basic neuroscience research. To verify the efficacy of the system and evaluation method as well as promote technical development in the lead-up to commercialization, the three companies will jointly provide the system to corporations and research institutions involved in drug development on a trial base. In addition to SCREEN providing the system, VitroVo will offer support for introducing the system by consulting on cell culture procedures, custom data analysis, and interpreting test results. At the same time, VitroVo will begin offering contract research services to verify the effectiveness of the system. This trial offer will allow the three companies to accelerate system development and market surveys based on feedback from users, with the goal of commercializing MEA systems utilizing CMOS-MEA systems utilizing CMOS- MEA systems utilizing CMOS -MEA: A device that uses complementary metal-oxide-semiconductor technology and a microelectrode array to detect cell electrical activity. Cell firing: The phenomenon in which nerve cells generate action potentials, causing electrical excitation, releasing neurotransmitters, and transmitting information.

SCREEN Holdings Co., Ltd. provided dividend guidance for the fiscal year ending March 31, 2026. for the year end, the company expects dividend of JPY 157.00 per share against JPY 188.00 per share a year ago.

SCREEN Holdings Co., Ltd. provided consolidated earnings guidance for six months ending September 30, 2025 and fiscal year ending March 31, 2026. For the six months, the company expects Net Sales of JPY 299,500 million, Operating income of JPY 54,500 million, Profit attributable to owners of parent of JPY 38,500 million and basic earnings per share of JPY 407.70. For the year, the company expects Net Sales of JPY 621,000 million, Operating income of JPY 117,000 million, Profit attributable to owners of parent of JPY 88,000 million and basic earnings per share of JPY 932.09.

SCREEN Holdings Co., Ltd. declared dividend for the fiscal year ended March 31, 2025 and provided dividend guidance for the second quarter end of fiscal year ending March 31, 2026. for the year end 2025, the company declared dividend of JPY 52.50 per share against JPY 50.50 per share a year ago. Scheduled date to commence dividend payments: June 23, 2025. Record date is March 31, 2025. This resolution will be voted on at the upcoming 84th ordinary general meeting of shareholders scheduled for June 20, 2025 for approval. For the second quarter end of 2026, the company expects dividend of JPY 123.00 per share against JPY 120.00 per share a year ago.

SCREEN Holdings Co., Ltd., Annual General Meeting, Jun 20, 2025, at 10:00 Tokyo Standard Time. Location: 5th Floor of the Head Office Building,Tenjinkita-machi 1-1, Teranouchi-agaru 4-chome, Horikawa-dori, Kamigyo-ku, Kyoto, Japan Japan Agenda: To consider the business report, the consolidated financial statements, and results of audit of the consolidated financial statements by the accounting auditor and the board of corporate auditors for the 84th fiscal term (from April 1, 2024 to March 31, 2025); to consider the non-consolidated financial statements for the 84th fiscal term (from April 1, 2024 to March 31, 2025); and to discuss other matters.

SCREEN Holdings Co., Ltd., Board Meeting, May 09, 2025. Agenda: To consider the distribution of dividend of surplus with record date of March 31, 2025.

SCREEN Holdings Co., Ltd., 2025 Earnings Call, May 09, 2025

The company closed its plan on April 7, 2025.

From April 1, 2025 to April 7, 2025, the company has repurchased 1,242,500 shares, representing 1.28% for ¥11,073.22 million. With this, the company has completed the repurchase of 2,979,300 shares, representing 3.06% for ¥29,999.82 million under the buyback announced on February 14, 2025.

From February 14, 2025 to March 31, 2025, the company has repurchased 1,736,800 shares, representing 1.78% for ¥18,926.6 million. With this, the company has completed the repurchase of 1,736,800 shares, representing 1.78% for ¥18,926.6 million under the buyback announced on February 14, 2025.

SCREEN Holdings Co., Ltd. announced that they will report fiscal year 2025 results on May 09, 2025

SCREEN Holdings Co., Ltd., Board Meeting, Feb 14, 2025. Agenda: To consider Status of Acquisition of Company Shares Under the Provisions of the Company's Articles of Incorporation, Pursuant to Article 165-2 of the Companies Act of Japan.

SCREEN Holdings Co., Ltd., Board Meeting, Feb 28, 2025. Agenda: To consider the resolution regarding recurrence prevention measures and disciplinary action for the parties involved in Accounting Issues.

The Board of Directors of SCREEN Holdings Co., Ltd. has authorized a buyback plan on February 14, 2025.

SCREEN Holdings Co., Ltd. (TSE:7735) announces a share repurchase program. Under the program, the company will repurchase 4,000,000 shares, representing 0.64% of the outstanding shares for ¥30,000 million. The purpose of the program is to improve shareholder returns and capital efficiency. The program will run until April 25, 2025. As of December 31, 2025, the company had 97,599,693 shares outstanding and 3,990,039 shares in treasury.

SCREEN Holdings Co., Ltd. revised earnings guidance for the Fiscal year ending March 31, 2025. For the year, the company expects net sales of JPY 616,000 million, operating income of JPY 126,000 million, profit attributable to owners of parent of JPY 91,500 million and basic earnings per share of JPY 940.48.

SCREEN Holdings Co., Ltd. revised dividend guidance for the fiscal year ending March 31, 2025. For the period, company expects dividend of JPY 163.00 per share against JPY 127 per share as previously Forecasted. The SCREEN Group maintains the basic policy to provide a consolidated dividend payout ratio of 30% or above, with an eye on the need to secure the retained earnings necessary for growth investment and maintain a sound financial base to respond to future changes in the business environment. Considering the above policy and the latest consolidated earnings forecast, company will revise the cash dividend forecast initially announced on October 31, 2024.

SCREEN Holdings Co., Ltd., Board Meeting, Jan 31, 2025. Agenda: To consider Revision of Year-end Cash Dividend Forecast for the Fiscal Year Ending March 31, 2025.

SCREEN Holdings Co., Ltd. expected to report Fiscal Year 2025 results on May 9, 2025. This event was calculated by S&P Global (Created on January 16, 2025).

SCREEN Holdings Co., Ltd. announced that they will report Q3, 2025 results at 3:35 PM, Tokyo Standard Time on Jan 31, 2025

SCREEN Holdings Co., Ltd., Q3 2025 Earnings Call, Jan 31, 2025

SCREEN Holdings Co., Ltd. reported earnings results for the half year ended September 30, 2024. For the half year, the company reported sales was JPY 277,399 million. Net income was JPY 38,838 million. Basic earnings per share from continuing operations was JPY 399.51. Diluted earnings per share from continuing operations was JPY 398.79.

SCREEN Holdings Co., Ltd. provided earnings guidance for the Fiscal year ending March 31, 2025. For the year, the company expects net sales of JPY 577,000 million, operating income of JPY 113,000 million, profit attributable to owners of parent of JPY 80,000 million and basic earnings per share of JPY 822.30.

SCREEN Holdings Co., Ltd., Board Meeting, Oct 31, 2024. Agenda: To consider the dividend.

SCREEN Holdings Co., Ltd. expected to report Q3 2025 results on January 31, 2025. This event was calculated by S&P Global (Created on January 14, 2025).

SCREEN Holdings Co., Ltd. announced the distribution of interim dividend of JPY 120 per share for the Fiscal Year Ending March 31, 2025 against dividend of JPY 167.00 per share paid a year ago. Record date is September 30, 2024 . Effective date is December 2, 2024. Provides dividend guidance for the fiscal year ending March 31, 2025. For the period, company expects dividend of JPY 127.00 per share against JPY 140 per share paid a year ago.

SCREEN Holdings Co., Ltd., Q2 2025 Earnings Call, Oct 31, 2024

Rege Nephro Co., Ltd. announced that it will receive ¥25,000 million in a round of funding led by new investor, DCI Partners Co., Ltd. on October 7, 2024. The transaction will include participation from mix of strategic investors including new investors, JIC Venture Growth Investments Co., Ltd., Nippon Venture Capital Co., Ltd., Tohoku University Venture Partners Co.,Ltd., Golden Asia Fund Venture Ltd., Mitsui Chemicals, Inc., Global Brain Corporation, Mitsubishi UFJ Capital Co., Ltd., Industrial Technology Investment Corporation, Shimadzu Corporation, SCREEN Holdings Co., Ltd., Chushin Venture Capital Co., Ltd., Senshu Ikeda Capital Co., Ltd., Toyo Seikan Group Holdings, Ltd., Asahi Kasei Corporation, QB Capital, LLC and i-Lab CVC1 Limited Liability Partnership, and returning investor, Kyoto University Innovation Capital Co., Ltd., JAFCO Group Co., Ltd., and other investors. On the same date, the company has received ¥22,500 million in its first tranche. The company has raised a total of ¥44,000 million in funding till date.

SCREEN Holdings Co., Ltd. announced that they will report Q2, 2025 results on Oct 31, 2024

IR Day of the fiscal year ending March 31, 2025

SCREEN Holdings Co., Ltd. provided earnings guidance for the six months ending September 30, 2024 and fiscal year ending March 31, 2025. For the six months, the company expects net sales of JPY 280,500 million, operating income of JPY 53,000 million, profit attributable to owners of parent of JPY 35,000 million, and basic earnings per share of JPY 360.46. For the year, the company expects net sales of JPY 564,500 million, operating income of JPY 105,000 million, profit attributable to owners of parent of JPY 75,000 million and basic earnings per share of JPY 772.35.

SCREEN Holdings Co., Ltd. revised dividend guidance for the second quarter of fiscal year ending March 31, 2025. For the period, the company expects to pay a dividend of JPY 109.00 per share against previous guidance of JPY 100.00 per share.

SCREEN Holdings Co., Ltd., Board Meeting, Jul 26, 2024. Agenda: To consider the revision of cash dividend forecast for the fiscal year ending March 31, 2025; and to discuss other matters.

SCREEN Holdings Co., Ltd., Q1 2025 Earnings Call, Jul 26, 2024

SCREEN Holdings Co., Ltd. expected to report First-Half, 2025 results on October 25, 2024. This event was calculated by S&P Global (Created on July 8, 2024).